SFA Therapeutics is revolutionizing the treatment of chronic inflammatory diseases with their innovative approach to drug discovery and development. Their groundbreaking platform utilizes microbiome-derived metabolites as drugs, offering a completely new paradigm for addressing these conditions. By deriving drugs from natural substances found in bacteria, SFA Therapeutics ensures faster clinical development, lower R&D costs, and safer treatments without genotoxicity.

Their pipeline includes a range of treatments for various conditions such as Psoriasis, Liver Cancer, Ophthalmic Diseases, and Cytokine Release Syndrome, among others. With over 85 chronic inflammatory diseases in their sights, SFA Therapeutics is dedicated to providing safer and more effective therapies than currently available options. Currently, SFA Therapeutics is focused on clinical development in areas including Autoimmune Diseases, Infectious Disease, Liver Diseases, Dermatology, Ophthalmology, and Oncology.

Their portfolio showcases their commitment to advancing medical science and improving patient outcomes. Stay up to date with the latest news and advancements from SFA Therapeutics as they continue to pave the way for a new era in chronic inflammatory disease treatments